210 related articles for article (PubMed ID: 17342095)
1. Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Spiegl-Kreinecker S; Pirker C; Marosi C; Buchroithner J; Pichler J; Silye R; Fischer J; Micksche M; Berger W
Br J Cancer; 2007 Mar; 96(6):960-9. PubMed ID: 17342095
[TBL] [Abstract][Full Text] [Related]
2. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
3. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
[No Abstract] [Full Text] [Related]
4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
7. Treatment considerations for MGMT-unmethylated glioblastoma.
Taylor JW; Schiff D
Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
[TBL] [Abstract][Full Text] [Related]
8. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Dehdashti AR; Hegi ME; Regli L; Pica A; Stupp R
Neurosurg Focus; 2006 Apr; 20(4):E6. PubMed ID: 16709037
[TBL] [Abstract][Full Text] [Related]
9. MGMT gene silencing and benefit from temozolomide in glioblastoma.
Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant temozolomide: how long and how much?
Franceschi E; Tosoni A; Brandes AA
Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
[No Abstract] [Full Text] [Related]
11. Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy.
Jahraus CD; Friedman AH
Tumori; 2010; 96(5):771-5. PubMed ID: 21302627
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Brandes AA; Tosoni A; Cavallo G; Bertorelle R; Gioia V; Franceschi E; Biscuola M; Blatt V; Crinò L; Ermani M;
Br J Cancer; 2006 Nov; 95(9):1155-60. PubMed ID: 17024124
[TBL] [Abstract][Full Text] [Related]
14. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
[TBL] [Abstract][Full Text] [Related]
15. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
16. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
18. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q
Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
[TBL] [Abstract][Full Text] [Related]
20. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
